Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease

NCT01126099 is registered in ClinicalTrials.gov with Seattle Institute for Biomedical and Clinical Research as lead sponsor.

NCT NCT01126099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01126099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Phase
Not applicable
Overall status
Completed
Start date
March 31, 2010
Completion date
March 31, 2014
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease